Dana-Farber Cancer Institute, Inc. vs Bristol-Myers Squibb Company et al.

Notice: refund approved

Decision Settlement Prior to Institution of Trial and Granting Joint Request to Treat Settlement Agreement as Business Confidential Information

Petitioner's Request for Refund of Post-Institution Fees

Exhibit 3001

Joint Motion to Terminate Pursuant to 35 U.S.C. § 317

Settlement

Joint Request that the Settlement Agreement be Treated as Business Confidential Information Pursuant to 35 U.S.C. § 317

ORDER Granting Petitioners Motions for Admission Pro Hac Vice of Katherine A. Helm and Noah M. Leibowitz 37 C.F.R. § 42.10 c

Ono Pharmaceuticals Co., Ltd.'s Power of Attorney

Petitioner Dana-Farber Cancer Institute, Inc.'s Unopposed Motion for Pro Hac Vice Admission of Katherine A. Helm, J.D., Ph.D.

Declaration of Katherine A. Helm in Support of Motion for Admission Pro Hac Vice

Petitioner Dana-Farber Cancer Institute, Inc.'s Unopposed Motion for Pro Hac Vice Admission of Noah M. Leibowitz

Declaration of Noah M. Leibowitz in Support of Motion for Admission Pro Hac Vice

Notice : Mandatory Notice

Notice : Power of Attorney

Notice: Notice filing date accorded

U.S. Patent No. 8,008,449 B2 (“the ’449 patent”)

Curriculum vitae of Dr. Gérard Zurawski

U.S. Patent No. 7,595,048

Ishida et al., Differential expression of PD-L1 and PD-L2, ligands for...

Iwai et al., Involvement of PD-L1 on tumor cells in the escape from host...

Ohigashi et al., Clinical significance of programmed death-1 ligand-1...

Greenwald et al., The B7 family revisited, Annual review of immunology...

Hirano et al., Blockade of B7-H1 and PD-1 by monoclonal antibodies...

Bristol-Myers Squibb Company et al v. AstraZeneca Pharmaceuticals LP et al.

PCT Publication No. WO 01/14557 A1

Stern, M., and R. Herrmann, Overview of monoclonal antibodies in cancer...

List of approved Antibodies from The Antibody Society

Vaughan et al., Human Antibodies by Design, Nature Biotechnology 16 (1998)

Hoogenboom et al., Antibody phage display technology and its...

File History For U.S. Patent No. 8,008,449 B2 - Part 1 (pages 1-421)

File History For U.S. Patent No. 8,008,449 B2 - Part 2 (pages 422-922)

File History For U.S. Patent No. 8,008,449 B2 - Part 3 (pages 923-1390)

File History For U.S. Patent No. 8,008,449 B2 - Part 4 (pages 1391-1980)

File History For U.S. Patent No. 8,008,449 B2 - Part 5 (pages 1981-2058)

PCT Publication No. WO 06/121168 A1

U.S. Provisional Patent Application No. 60/679,466

U.S. Provisional Patent Application No. 60/738,434

U.S. Provisional Patent Application No. 60/748,919

European Patent No. EP2161336 B1

Notice of Intent to Grant Application No. 09013687.0, dated Feb. 25, 2013

Merck & Co., Inc’s April 30, 2014 Notice of Opposition of EP2161336 B1

Novartis AG’s April 25, 2014 Notice of Opposition of EP2161336 B1

4-Antibody AG’s April 29, 2014 Notice of Opposition of EP2161336 B1

Janssen Biotech, Inc.’s April 30, 2014 Notice of Opposition of EP2161336 B1

Declaration of Jennifer Mataraza, dated April 28, 2014, submitted on...

Declaration of Robert J. Bloch, dated April 29, 2014, submitted on...

European Patent No. EP2161336 B1 Amended claims with annotations, dated...

European Patent Opposition Division March 2, 2017 Decision To maintain...

Bristol-Myers Squibb Company et al v. AstraZeneca Pharmaceuticals LP et al.

PCT Publication No. WO 4/056875 A1

PCT Publication No. WO 17/011666 A1

Holm et al., CD4+ CD25+ regulatory T cells: I. Phenotype and physiology,...

Thornton, Angela M., and Ethan M. Shevach, CD4+ CD25+ immunoregulatory T...

Gavin et al., Homeostasis and anergy of CD4+ CD25+ suppressor T cells in...

Cai et al., PD-1 ligands, negative regulators for activation of naive,...

Response to Examination report, dated April 4, 2012, in European Patent...

Daugherty, Ann L., and Randall J. Mrsny, Formulation and delivery issues...

Bindon et al., Human monoclonal IgG isotypes differ in complement...

Conrath et al., Camel single-domain antibodies as modular building units...

Lindhofer et al., Bispecific antibodies target operationally...

Maynard, Jennifer, and George Georgiou, Antibody engineering, Annual...

Zurawski et al., The Primary Binding Subunit of the Human Interleukin-4...

Parks et al., Flow cytometry and fluorescence-activated cell sorting,...

PÉREZ, De La Lastra, and B. E. R. G. Van Den, Epitope mapping of 10...

Tosi et al., Quantitative immunofluorescent assay of full-length,...

Sims et al., Effect of platelet activation on the conformation of the...

Product information for Anti-Human PDCD1 Recombinant Antibody (PD1-17)...

Product Information for Anti-PD-1 [PD1-28], Human IgG1, Lambda Absolute...

Flamar et al., Non-covalent Assembly of Anti-Dendritic Cell Antibodies...

Product information for Q15116 PDCD1_HUMAN available at...

Product information for CHOgro® High Yield Expression System available...

Product information for Fluorescent Protein Labeling Kits available at...

Vaswani, et al., Humanized antibodies as potential therapeutic drugs,...

GenBank® Accession No. BC074740.2, GI No. 50960296, "Homo sapiens...

U.S. Patent No. 9,580,505

U.S. Patent No. 9,580,507

Staerz et al., Hybrid antibodies can target sites for attack by T cells,...

Perez et al., Specific targeting of cytotoxic T cells by anti-T3 linked to

Staerz and Bevan, Hybrid hybridoma producing a bispecific monoclonal...

Staerz and Bevan, Use of anti-receptor antibodies to focus T-Cell...

April 10, 2012 Proposed Claims, European Patent No. EP2161336 B1

Novartis AG’s April 25, 2014 Arguments in Support of Opposition of European

4-Antibody AG’s April 29, 2014 Arguments in Support of Opposition of...

Janssen Biotech, Inc.’s April 30, 2014 Arguments in Support of...

Vector information for pIRES2 DsRed-Express2 Vector

Janeway CA Jr et al. Immunobiology: The Immune System in Health and...

Wang et al., In vitro characterization of the anti-PD-1 antibody...

List of Materials Considered by Dr. Gérard Zurawski

Declaration of Dr. Gérard Zurawski

Petition : as filed

Notice : Power of Attorney